Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation.

Nordell AD, McKenna M, Borges ÁH, Duprez D, Neuhaus J, Neaton JD; INSIGHT SMART, ESPRIT Study Groups; SILCAAT Scientific Committee.

J Am Heart Assoc. 2014 May 28;3(3):e000844. doi: 10.1161/JAHA.114.000844.

2.

Factors associated with D-dimer levels in HIV-infected individuals.

Borges AH, O'Connor JL, Phillips AN, Baker JV, Vjecha MJ, Losso MH, Klinker H, Lopardo G, Williams I, Lundgren JD; INSIGHT SMART Study Group; ESPRIT Study Group; SILCAAT Scientific Committee.

PLoS One. 2014 Mar 13;9(3):e90978. doi: 10.1371/journal.pone.0090978. eCollection 2014.

3.

Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.

Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM; INSIGHT SMART Study Group.

PLoS One. 2013;8(2):e56249. doi: 10.1371/journal.pone.0056249. Epub 2013 Feb 15.

4.

Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: a retrospective multicenter study.

Torres HA, Nevah MI, Barnett BJ, Mahale P, Kontoyiannis DP, Hassan MM, Raad II.

J Clin Virol. 2012 Jul;54(3):218-22. doi: 10.1016/j.jcv.2012.03.002. Epub 2012 Mar 28.

PMID:
22459004
5.

Oral and tympanic membrane temperatures are inaccurate to identify Fever in emergency department adults.

Barnett BJ, Nunberg S, Tai J, Lesser ML, Fridman V, Nichols P, Powell R, Silverman R.

West J Emerg Med. 2011 Nov;12(4):505-11. doi: 10.5811/westjem.2011.2.1963.

6.

Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.

Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, Skoutelis A, Goetz MB, Phillips AN; INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group.

J Infect Dis. 2009 Sep 15;200(6):973-83. doi: 10.1086/605447.

7.

Interruption of antiretroviral therapy is associated with increased plasma cystatin C.

Mocroft A, Wyatt C, Szczech L, Neuhaus J, El-Sadr W, Tracy R, Kuller L, Shlipak M, Angus B, Klinker H, Ross M; INSIGHT SMART Study Group.

AIDS. 2009 Jan 2;23(1):71-82. doi: 10.1097/QAD.0b013e32831cc129.

8.

Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen.

Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J; SMART Study Group.

AIDS. 2008 Nov 12;22(17):2279-89. doi: 10.1097/QAD.0b013e328311d16f.

9.

Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

Ann Intern Med. 2008 Sep 2;149(5):289-99.

PMID:
18765698
10.

Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

J Infect Dis. 2008 Apr 15;197(8):1145-55. doi: 10.1086/529523.

11.

Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

J Infect Dis. 2008 Apr 15;197(8):1133-44. doi: 10.1086/586713.

12.

Alopecia associated with ritonavir-boosted atazanavir therapy.

Torres HA, Barnett BJ, Arduino RC.

AIDS. 2007 Jun 19;21(10):1391-2. No abstract available.

PMID:
17545728
13.

Tongue hyperpigmentation in a caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.

Torres HA, Bull L, Arduino RC, Barnett BJ.

Am J Gastroenterol. 2007 Jun;102(6):1334-5. No abstract available.

PMID:
17531028
14.

Use of fosamprenavir, a sulfa-containing protease inhibitor, in HIV-infected patients with glucose-6-phosphate dehydrogenase deficiency.

Torres HA, Barnett BJ, Arduino RC.

Clin Infect Dis. 2007 Mar 15;44(6):887-8. No abstract available.

15.

Acute human immunodeficiency virus infection presenting as disseminated gonococcal infection.

Amir O, Nguyen VD, Barnett BJ.

South Med J. 2003 Mar;96(3):284-6. No abstract available.

PMID:
12659361
16.
17.

Solitary parietal lobe histoplasmoma mimicking a brain tumor.

Paphitou NI, Barnett BJ.

Scand J Infect Dis. 2002;34(3):229-32.

PMID:
12030405
18.

HIV-treating physicians in Houston express their professional opinions on the public health implications of antiretroviral therapy.

Crofoot G, Barnett BJ, Nannini EC, Salvato PD.

Res Initiat Treat Action. 2000 Dec;6(4):19-22. No abstract available.

PMID:
11708170
19.

Information order and outcome framing: an assesment of judgment bias in a naturalistic decision-making context.

Perrin BM, Barnett BJ, Walrath L, Grossman JD.

Hum Factors. 2001 Summer;43(2):227-38.

PMID:
11592664
20.

Native valve endocarditis due to Bartonella henselae in a middle-aged human immunodeficiency virus-negative woman.

De La Rosa GR, Barnett BJ, Ericsson CD, Turk JB.

J Clin Microbiol. 2001 Sep;39(9):3417-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk